Acrux Ltd has released a press release.
Appendix 4D and Half Year Report to 31 December 2016
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Acrux
- Axiron Net Sales, Quarter to December2016
- S&P DJ Indices Announces March Quarterly Review
- European approvals and milestone payments for Lenzetto
- IPR Petition Filed Against Key Jublia Patent
- New intellectual property application for onychomycosis
Later from Acrux
- Axiron Net Sales Quarter to 31 March 2017
- Institution of IPR Proceeding Against Key Jublia Patent
- Axiron Generic Launched In The United States
- Axiron Net Sales Quarter to 30 June 2017
- Teva Launches Generic Version of Axiron in United States
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux